These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11213858)

  • 1. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction.
    Tsikouris JP; Tsikouris AP
    Pharmacotherapy; 2001 Feb; 21(2):207-17. PubMed ID: 11213858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bolus fibrinolytic therapy in acute myocardial infarction.
    Llevadot J; Giugliano RP; Antman EM
    JAMA; 2001 Jul; 286(4):442-9. PubMed ID: 11466123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
    Tanswell P; Modi N; Combs D; Danays T
    Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of tenecteplase in acute myocardial infarction.
    Guerra DR; Karha J; Gibson CM
    Expert Opin Pharmacother; 2003 May; 4(5):791-8. PubMed ID: 12740001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenecteplase: a review.
    Davydov L; Cheng JW
    Clin Ther; 2001 Jul; 23(7):982-97; discussion 981. PubMed ID: 11519775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review.
    Dundar Y; Hill R; Dickson R; Walley T
    QJM; 2003 Feb; 96(2):103-13. PubMed ID: 12589008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenecteplase for treatment of acute myocardial infarction.
    Turcasso NM; Nappi JM
    Ann Pharmacother; 2001 Oct; 35(10):1233-40. PubMed ID: 11675853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
    Noble S; McTavish D
    Drugs; 1996 Oct; 52(4):589-605. PubMed ID: 8891469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
    Weaver WD
    Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on reteplase in thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
    Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
    Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.
    Meierhenrich R; Carlsson J; Seifried E; Pfarr E; Smolarz A; Neuhaus KL; Tebbe U
    Int J Cardiol; 1998 Jun; 65(1):57-63. PubMed ID: 9699932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reteplase: a review of its use in the management of thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
    Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
    Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East.
    Al-Zakwani I; Ali A; Zubaid M; Panduranga P; Sulaiman K; Abusham A; Almahmeed W; Al-Motarreb A; Al Suwaidi J; Amin H
    J Thromb Thrombolysis; 2012 Apr; 33(3):280-6. PubMed ID: 22359050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Tenecteplase--the best among the equals.".
    Saran RK; Sethi R; Nagori M
    Indian Heart J; 2009; 61(5):454-8. PubMed ID: 20635761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction.
    Wooster MB; Luzier AB
    Ann Pharmacother; 1999 Mar; 33(3):318-24. PubMed ID: 10200858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.